Ind-Swift Laboratories Ltd's Q3FY25 Quarter Results
- 14 Feb 2025
Result Summary
- Ind-Swift Laboratories Ltd reported a 9.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a decline of 92.4%.
- Its expenses for the quarter were down by 3.4% QoQ and 91.3% YoY.
- The net profit decreased 97.6% QoQ and decreased 99.9% YoY.
- The earnings per share (EPS) of Ind-Swift Laboratories Ltd - at - during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 22.48 | 24.96 | 294.63 | -9.9% | -92.4% |
Total Expenses | 23.56 | 24.38 | 270.85 | -3.4% | -91.3% |
Profit Before Tax | -1.08 | 0.58 | 23.78 | -286.2% | -104.5% |
Tax | -1.08 | 0.18 | 4.25 | -700.0% | -125.4% |
Profit After Tax | 0.01 | 0.41 | 19.42 | -97.6% | -99.9% |
Earnings Per Share | 0.00 | 0.10 | 3.30 | -100.0% | -100.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Ind-Swift Laboratories Ltd is a pharmaceutical company engaged primarily in the development, manufacturing, and marketing of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates in the healthcare sector, providing products that cater to various therapeutic segments. Ind-Swift Laboratories has been a part of the pharmaceutical industry, focusing on innovation and quality in its offerings. Any recent major developments within the company are not available in the provided data.
Revenue
For the third quarter of the fiscal year 2025 (Q3FY25), Ind-Swift Laboratories Ltd reported total income of ₹22.48 crores. This represents a decline of 9.9% compared to the previous quarter (Q2FY25), where total income was ₹24.96 crores. Year-over-year, there is a substantial decrease of 92.4% from Q3FY24, during which the total income was ₹294.63 crores. This significant reduction in total income reflects changes in the company's revenue generation over the year.
Profitability
In Q3FY25, the company recorded a Profit Before Tax (PBT) of -₹1.08 crores. This marks a notable decrease from the previous quarter's PBT of ₹0.58 crores, resulting in a quarter-over-quarter change of -286.2%. Compared to the same quarter in the previous fiscal year (Q3FY24), where PBT was ₹23.78 crores, the year-over-year change is -104.5%. Profit After Tax (PAT) for Q3FY25 is ₹0.01 crores, showing a decrease of 97.6% from Q2FY25's PAT of ₹0.41 crores and a 99.9% fall year-over-year from ₹19.42 crores. These figures indicate major shifts in profitability.
Operating Metrics
The earnings per share (EPS) in Q3FY25 was ₹0.00, down from ₹0.10 in Q2FY25, indicating a 100% decrease quarter-over-quarter. Comparing year-over-year with Q3FY24, when EPS was ₹3.30, there is a 100% decline. Total expenses for Q3FY25 were ₹23.56 crores, a slight reduction of 3.4% from Q2FY25's ₹24.38 crores, and a 91.3% decrease from Q3FY24's expenses of ₹270.85 crores. The tax expense in Q3FY25 was -₹1.08 crores, contrasting significantly with both the previous quarter's tax of ₹0.18 crores and the tax of ₹4.25 crores in Q3FY24, reflecting a -700.0% quarter-over-quarter change and -125.4% year-over-year change.
